PMN
ProMIS Neurosciences Inc.
9.20$
+0.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | -60.3% | +1,638.8% | -22.8% | -27.8% | -30.3% | +125.6% | -57.2% | +634.1% | -15.9% | |
| – | – | – | -60.3% | +1,638.8% | -22.8% | -27.8% | -30.3% | +125.6% | -57.2% | +614.5% | -13.6% | |
| – | – | – | -60.3% | +2,070.0% | -38.3% | -37.1% | -46.1% | +241.4% | -60.3% | +943.3% | -16.3% | |
| – | – | – | -59.5% | +2,004.7% | -38.2% | -37.0% | -45.9% | +239.7% | -60.1% | +938.1% | -16.3% | |
| – | – | – | -5.9% | +772.3% | -87.6% | -30.1% | -46.0% | +191.9% | -57.6% | +552.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +6.2% | +367.6% | -85.9% | +72.3% | +136.9% | +24.0% | -14.9% | -35.9% | +9.0% | |
| – | – | – | +19.9% | -16.9% | -15.8% | +82.8% | +142.2% | +24.3% | -14.7% | -36.5% | +9.1% | |
| – | – | – | +43.6% | -21.8% | +10.3% | -30.9% | +131.7% | +51.5% | -39.6% | -32.5% | +4.5% | |
| – | – | – | -3,053.4% | – | +126.7% | -42.6% | -104.0% | – | -113.7% | – | -18.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3,716.4% | -95.9% | +1.2% | +52.1% | +15.8% | +0.1% | +0.0% | +0.0% | +26.0% | +271.5% | +40.1% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.